PureTech Health plc (LON:PRTC)
126.40
+0.40 (0.32%)
May 6, 2026, 3:13 PM GMT
PureTech Health Revenue
In the year 2025, PureTech Health had annual revenue of $4.66M USD, down -3.50%. PureTech Health had revenue of $2.81M in the half year ending December 31, 2025, with 1,460.00% growth.
Revenue
$4.66M
Revenue Growth
-3.50%
P/S Ratio
88.60
Revenue / Employee
$83.20K
Employees
56
Market Cap
306.71M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.66M | -169.00K | -3.50% |
| Dec 31, 2024 | 4.83M | 1.50M | 44.98% |
| Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
| Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
| Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
| Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
| Dec 31, 2019 | 9.81M | -10.94M | -52.73% |
| Dec 31, 2018 | 20.75M | 18.21M | 718.46% |
| Dec 31, 2017 | 2.54M | -1.90M | -42.79% |
| Dec 31, 2016 | 4.43M | -7.40M | -62.54% |
| Dec 31, 2015 | 11.83M | 9.61M | 432.31% |
| Dec 31, 2014 | 2.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genus | 672.00M |
| Oxford Nanopore Technologies | 223.90M |
| Oxford Biomedica | 168.74M |
| hVIVO | 49.66M |
| Bioventix | 12.54M |
| Scancell Holdings | 4.71M |
| 4basebio | 1.78M |
| Ondine Biomedical | 1.18M |
PureTech Health News
- 6 days ago - PureTech Health PLC (PTCHF) Full Year 2025 Earnings Call Highlights: Strategic Innovations and ... - GuruFocus
- 6 days ago - Full Year 2025 PureTech Health PLC Earnings Call Transcript - GuruFocus
- 7 days ago - PureTech Health Earnings Call Transcript: H2 2025 - Transcripts
- 7 days ago - PureTech Health (PRTC) to Delist from Nasdaq, Remaining Listed on London Stock Exchange - GuruFocus
- 7 days ago - PureTech Announces Annual Results for Year Ended December 31, 2025 - Business Wire
- 7 days ago - PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange - Business Wire
- 9 days ago - PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors - Business Wire
- 14 days ago - Positive Phase 1b Results for PureTech Health (PRTC) - GuruFocus